ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Overcoming resistance mechanisms in cancer immunotherapy-novel approaches and combinations.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance in cancer cells is a significant challenge for modern oncology, demanding the development of novel therapeutic techniques. This review examines new approaches to reducing drug resistance in cancer cells, with an emphasis on developing therapeutic options. Complex molecular findings into medication resistance in this article discuss genetic mutations, efflux pumps, altered signaling pathways, and micro environmental impacts. Targeted medicines, combination therapy, immunotherapies, and precision medicine methods are discussed as promising options. Combining standard cytotoxic medicines with molecularly targeted inhibitors results in synergistic effects. The routes used to avoid resistance are investigated. This article examines how immunotherapeutic approaches like immune checkpoint inhibitors and adoptive cell therapies can improve anti-tumor immune responses and overcome immune evasion mechanisms. Biomarker-driven techniques are crucial for predicting and monitoring therapy responses, leading to improved therapeutic results. This review examines the impact of medication resistance on cancer therapy paradigms and their potential future direction. Integrating developing therapeutic options can address problems and improve patient outcomes.
Indexed as
Identifiers
40498093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.